10 results about "Hot flash" patented technology

The invention discloses an artificial intelligence female climacteric medical data auxiliary processing method and system, and relates to the technical field of medical data auxiliary processing. The monitoring module is set, the monitoring module is a wearable intelligent device, physical sign information data and environment information data of a target patient are obtained based on the monitoring module, and feature information items and environment information items are obtained; the acquisition module is used for acquiring questionnaire score information of a target patient to obtain questionnaire information items; by setting the monitoring module of the wearable intelligent device, the typical hot tide phenomenon of female climacteric is accurately captured, body surface temperature and current change data are obtained through a micro heat-sensitive sensor and a micro current sensor, accurate feature information items are obtained through strict threshold judgment, meanwhile, environment information data such as noise and illumination can be obtained, and the intelligent female climacteric monitoring system is suitable for being used for monitoring female climacteric climacteric conditions. Interference of environmental factors on female endocrine and climacteric symptoms is comprehensively considered.

The application discloses a bird's nest compound product with the effect of improving female body health and a preparation method and application thereof. The preparation method comprises the following steps: mixing red ginseng, Gastrodia elata, ophiopogon, donkey-hide gelatin, eucommia and ganoderma lucidum with a solvent to form a mixed slurry; treating and extracting the mixed slurry by applying an electric field to prepare a compound liquid; and mixing the compound liquid with bird's nest to prepare the bird's nest compound product with the effect of improving female body health. The bird's nest is matched with the medicine-food homologous material, and on the basis of the theory of "suo zhuo jun chen", the bird's nest compound product capable of obviously improving menopausal syndrome is prepared, the hormone level is effectively adjusted, symptoms such as hot flashes, night sweats, sleep quality improvement, ovary and uterus repair promotion and the like are relieved, and the product is mild in action, high in safety, good in flavor and color.

The application discloses a traditional Chinese medicine preparation for treating tachycardia, which is prepared from the following raw medicinal materials: cassia twig 10-20 g, white atractylodes 10-20 g, radix codonopsis 15-25 g, prepared rehmannia 15-25 g, raw oyster shell 25-35 g, raw concha mallei 25-35 g, sophora flavescens 10-20 g, schisandra chinensis 10-20 g, gancao 15-25 g, ophiopogon japonicus 10-20 g, and turtle shell 10-20 g. The traditional Chinese medicine preparation for treating tachycardia is orally taken in a daily dose, and is taken twice a day, in the morning and in the evening, half an hour after meals, and is continuously taken for 4 weeks as a treatment course. The traditional Chinese medicine preparation for treating tachycardia can obviously improve symptoms such as palpitation, short breath, five heart heat, hot flashes, insomnia, dreaminess, anxiety and the like, has a remarkable curative effect, is safe, is cheap and simple, and has a high clinical promotion value.

The present disclosure relates to compositions comprising an aqueous solution of at least about 70% by weight water in combination with selected fatty acid salts and optionally an alcohol and / or a cooling sensate, as well as methods of using the same to treat symptoms of hot flashes. The fatty acid salts form fiber-like crystalline particles that together form a self-supporting mesh structure with voids, the aqueous solution being contained in the voids. When the composition is compressed above a critical stress, the mesh allows for the entrapped aqueous solution to be expressed.

1. The name of the design product: electronic device's vasomotor symptom severity record graphical user interface. 2. The use of the design product: for an electronic device. 3. The design points of the design product: in the graphical user interface. 4. The picture or photo that best indicates the design points: design 1 interface change state diagram 2. 5. The usual design, omit other views of the electronic device. 6. Design 1 is designated as the basic design. 7. The use of the graphical user interface: for patients to record the severity of symptoms of vasomotor symptoms. 8. Other circumstances that need to be explained: the user clicks on any one of the buttons representing the degree of "mild", "moderate" and "severe" according to the degree of hot flashes in the main view of design 1, the interface jumps to design 1 interface change state diagram 1, clicks on the "confirm" button of the pop-up window in design 1 interface change state diagram 1, the interface jumps to design 1 interface change state diagram 2; the human-computer interaction mode of design 2 is the same as that of design 1.

Provided herein are methods for treating patients, including patients in need of analgesic treatment, as well as reducing the likelihood of abuse of opioids and opioid compounds (e.g., class II, class III and class IV analgesics) in the treated patient and reducing, eliminating and / or preventing hectic fever, hidrosis and / or pruritus side effects. The methods comprise administering to a patient once a day an immediate release composition comprising Cibopadol in form of Form A and / or free base.

A wearable device, such as a garment or containing garment portions, for managing and / or reducing the symptoms of a hot flash in a subject. The device comprises: a first set of components, each comprising a fabric comprising a cooling yarn; a second set of components, each comprising a quick-dry wicking fabric; and a third set of components, each comprising a phase change material fabric, wherein the first set of components are adapted to cover at least a neckline region and a peripheral region that extends adjacently around the armpit and the clavicle of the subject; the second set of components are adapted to cover at least the abdominal muscles and the lumbar regions of the subject; and the third set of components are adapted to cover at least the mammary and the dorsum regions of the subject.

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.

This invention belongs to the field of pharmaceutical technology, specifically relating to a composition for improving perimenopausal symptoms. It comprises the following components: 400-700 parts protein, 30-50 parts fat, 120-170 parts carbohydrates, 40-90 parts dietary fiber, 30-80 parts food-grade medicinal materials, 2-6 parts complex trace minerals, 50-95 parts complex macrominerals, 3-5 parts complex vitamins, and 5-10 parts blueberry powder. The protein is composed of whey protein, soy protein, and collagen peptides in a mass ratio of 7-12:6.1-8.5:1. By precisely controlling the ratio of soy protein and collagen peptides in the protein, this composition can significantly improve perimenopausal symptoms such as hot flashes, insomnia, osteoporosis, decreased estrogen levels, and uterine atrophy.

To provide a method for treating hot flash in a subject.SOLUTION: A method has administering a therapeutically effective amount of a transient receptor potential channel (TRP channel) blocker or pharmaceutically acceptable salt thereof. Preferably, the TRP channel blocker is a TRP channel subfamily V member 1 (TRPV1) blocker, or a pharmaceutical equivalent, analog, derivative, or salt thereof.SELECTED DRAWING: None